Sensimed receives the “Local to Global” Award by PwC

Sensimed is proud to announce the company received the “Coup-de-coeur” Award delivered by PwC’s Accelerator as one of the most promising innovative business projects.  

SENSIMED received product registration in Australia and Canada

Sensimed announced today the registration and commercialization in Australia and Canada of the SENSIMED Triggerfish®.  

SENSIMED to open distribution channels in Europe

Sensimed announced today the company has signed cooperation agreements in Spain, Portugal, UK and Ireland to strengthen its sales, service and support network in Europe.   

Patient recruitment completed for the first USA clinical study

SENSIMED announced today the completion of the first clinical study investigation in the USA. SENSIMED Triggerfish is considered to be a non-significant risk (NSR) device for the conduct of clinical investigation in the USA following recent consultation with FDA.  

SENSIMED and NIDEK to cooperate in Japan

SENSIMED announced today the company has agreed a cooperation agreement with NIDEK CO., LTD to support the clinical research phase and to develop the registration path for the SENSIMED Triggerfish® in Japan. Founded in Gamagori, Japan in 1971, NIDEK continues to be a global leader in the design, manufacture and distribution of ophthalmic equipment.

SENSIMED adds Key Executives to the Management Team

SENSIMED announced today the addition of key executives to the management team, Dr. René Goedkoop as Chief Medical Officer (CMO) and Stig Visti Andersen as Vice-President Sales and Marketing. In addition, Dr. Kaweh Mansouri will serve as Medical Director for the company.